[이코노믹리뷰=곽예지 기자] The Ministry of Food and Drug Safety is planning to detect 9 medicines manufactured differently from the license requirements in non-conservative pharmaceuticals, and to conduct an emergency inspection at 30 entrusted and entrusted manufacturing facilities nationwide.
The Ministry of Food and Drug Safety conducted an emergency special inspection at 30 subcontracted and entrusted manufacturing establishments nationwide as it confirmed that pharmaceuticals were manufactured (including consignment manufacturing) different from those approved and reported by non-conservative pharmaceuticals through regular inspections on the 12th. Said that.
This measure is a result of confirming that non-preservation pharmaceuticals manufactured 4 drugs for sale manufactured by the company and 5 drugs consigned by other companies to manufacture differently from the license requirements.
The nine drugs that have been confirmed to be illegally manufactured are ▲ non-conservative pharmaceutical distrin capsule (diaserine) ▲ non-conservative pharmaceutical redisin capsule ▲ non-conservative pharmaceutical mucolide capsule 200 mg (acetylcysteine) ▲ non-conservative pharmaceutical drug J-Ok Tin tablet (thioctic acid) ▲NewGen Pharm Diagen Capsule (Diacerain) ▲Huvist Pharm Atroserine Capsule (Diacerain) ▲Nexfam Korea Mucoban Capsule 200mg (Acetylcysteine) ▲Dasan Pharm Mucotia Capsule 200mg( Acetylcysteine) ▲ Medics Pharmaceuticals Thioxin Tablet (thioctic acid), etc.
The Ministry of Food and Drug Safety decided to temporarily suspend the manufacture and sale of the item and take measures to collect it.
The Ministry of Food and Drug Safety has distributed a safety bulletin to doctors, pharmacists, and consumers, requesting cooperation to convert the product to other alternative medicines and ensure proper product recall to experts such as medical and pharmacists.
The Ministry of Food and Drug Safety said, “In consideration of the inspection results, we plan to quickly prepare and promote comprehensive system improvement measures to prevent recurrence, such as expanding the inspection of the entire pharmaceutical manufacturing plant in the future.”